Find clinical trials for Non-Hodgkin Lymphoma in Cleveland, OH
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near Cleveland, OH, USA:
-T treatment.This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non- ...
Phase 1
Cleveland, Ohio, United States and 1 other location
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
Cleveland, Ohio, United States and 16 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Cleveland, Ohio, United States and 41 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Cleveland, Ohio, United States and 58 other locations
of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse...
Phase 1, Phase 2
Cleveland, Ohio, United States and 29 other locations
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...
Phase 1
Cleveland, Ohio, United States and 14 other locations
Carcinoma (NPC) and Non-Hodgkin Lymphoma (NHL) in Escalation and diffuse large B-cell lymphoma (DLBCL) in expans...
Phase 1, Phase 2
Cleveland, Ohio, United States and 17 other locations
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...
Phase 2
Cleveland, Ohio, United States and 140 other locations
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in...
Phase 1, Phase 2
Cleveland, Ohio, United States and 11 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...
Phase 1, Phase 2
Cleveland, Ohio, United States and 55 other locations
Clinical trials
Research sites
Resources
Legal